These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 37026714)

  • 61. SPECTRA Phase 2b Study: Impact of Sotatercept on Exercise Tolerance and Right Ventricular Function in Pulmonary Arterial Hypertension.
    Waxman AB; Systrom DM; Manimaran S; de Oliveira Pena J; Lu J; Rischard FP
    Circ Heart Fail; 2024 May; 17(5):e011227. PubMed ID: 38572639
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Sotatercept for the Treatment of Pulmonary Arterial Hypertension.
    Humbert M; McLaughlin V; Gibbs JSR; Gomberg-Maitland M; Hoeper MM; Preston IR; Souza R; Waxman A; Escribano Subias P; Feldman J; Meyer G; Montani D; Olsson KM; Manimaran S; Barnes J; Linde PG; de Oliveira Pena J; Badesch DB;
    N Engl J Med; 2021 Apr; 384(13):1204-1215. PubMed ID: 33789009
    [TBL] [Abstract][Full Text] [Related]  

  • 63. NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension.
    Mulvaney EP; Reid HM; Bialesova L; Bouchard A; Salvail D; Kinsella BT
    BMC Pulm Med; 2020 Apr; 20(1):85. PubMed ID: 32252727
    [TBL] [Abstract][Full Text] [Related]  

  • 64. RAGE-mediated extracellular matrix proteins accumulation exacerbates HySu-induced pulmonary hypertension.
    Jia D; He Y; Zhu Q; Liu H; Zuo C; Chen G; Yu Y; Lu A
    Cardiovasc Res; 2017 May; 113(6):586-597. PubMed ID: 28407046
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Loss of SMAD3 Promotes Vascular Remodeling in Pulmonary Arterial Hypertension via MRTF Disinhibition.
    Zabini D; Granton E; Hu Y; Miranda MZ; Weichelt U; Breuils Bonnet S; Bonnet S; Morrell NW; Connelly KA; Provencher S; Ghanim B; Klepetko W; Olschewski A; Kapus A; Kuebler WM
    Am J Respir Crit Care Med; 2018 Jan; 197(2):244-260. PubMed ID: 29095649
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Evaluation of pulmonary arterial pressure in patients with connective tissue disease-associated pulmonary arterial hypertension by myocardial perfusion imaging.
    Wang Z; Li J; Wang X; Liu M; Liao M; Zhang C; Shang X
    Ann Noninvasive Electrocardiol; 2022 Mar; 27(2):e12927. PubMed ID: 34908208
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Targeting peptidyl-prolyl isomerase 1 in experimental pulmonary arterial hypertension.
    Rai N; Sydykov A; Kojonazarov B; Wilhelm J; Manaud G; Veeroju S; Ruppert C; Perros F; Ghofrani HA; Weissmann N; Seeger W; Schermuly RT; Novoyatleva T
    Eur Respir J; 2022 Aug; 60(2):. PubMed ID: 35058248
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Genetics and genomics of pulmonary arterial hypertension.
    Soubrier F; Chung WK; Machado R; Grünig E; Aldred M; Geraci M; Loyd JE; Elliott CG; Trembath RC; Newman JH; Humbert M
    J Am Coll Cardiol; 2013 Dec; 62(25 Suppl):D13-21. PubMed ID: 24355637
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Mechanisms and treatment of pulmonary arterial hypertension.
    Ghofrani HA; Gomberg-Maitland M; Zhao L; Grimminger F
    Nat Rev Cardiol; 2024 Aug; ():. PubMed ID: 39112561
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Involvement of the bone morphogenetic protein system in endothelin- and aldosterone-induced cell proliferation of pulmonary arterial smooth muscle cells isolated from human patients with pulmonary arterial hypertension.
    Yamanaka R; Otsuka F; Nakamura K; Yamashita M; Otani H; Takeda M; Matsumoto Y; Kusano KF; Ito H; Makino H
    Hypertens Res; 2010 May; 33(5):435-45. PubMed ID: 20186146
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Novel therapeutic approaches for pulmonary arterial hypertension: Unique molecular targets to site-specific drug delivery.
    Vaidya B; Gupta V
    J Control Release; 2015 Aug; 211():118-33. PubMed ID: 26036906
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Codependence of Bone Morphogenetic Protein Receptor 2 and Transforming Growth Factor-β in Elastic Fiber Assembly and Its Perturbation in Pulmonary Arterial Hypertension.
    Tojais NF; Cao A; Lai YJ; Wang L; Chen PI; Alcazar MAA; de Jesus Perez VA; Hopper RK; Rhodes CJ; Bill MA; Sakai LY; Rabinovitch M
    Arterioscler Thromb Vasc Biol; 2017 Aug; 37(8):1559-1569. PubMed ID: 28619995
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension.
    Pullamsetti SS; Sitapara R; Osterhout R; Weiss A; Carter LL; Zisman LS; Schermuly RT
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628831
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Gene delivery of cytochrome p450 epoxygenase ameliorates monocrotaline-induced pulmonary artery hypertension in rats.
    Zheng C; Wang L; Li R; Ma B; Tu L; Xu X; Dackor RT; Zeldin DC; Wang DW
    Am J Respir Cell Mol Biol; 2010 Dec; 43(6):740-9. PubMed ID: 20118222
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
    Kabunga P; Coghlan G
    Drugs; 2008; 68(12):1635-45. PubMed ID: 18681488
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Emerging molecular targets for anti-proliferative strategies in pulmonary arterial hypertension.
    Tu L; Guignabert C
    Handb Exp Pharmacol; 2013; 218():409-36. PubMed ID: 24092350
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.
    Ruopp NF; Cockrill BA
    JAMA; 2022 Apr; 327(14):1379-1391. PubMed ID: 35412560
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effect of free and nanoemulsified β-caryophyllene on monocrotaline-induced pulmonary arterial hypertension.
    Carraro CC; Turck P; Bahr A; Donatti L; Corssac G; Lacerda D; da Rosa Araujo AS; de Castro AL; Koester L; Belló-Klein A
    Biochim Biophys Acta Mol Cell Res; 2024 Apr; 1871(4):119704. PubMed ID: 38462075
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Advances in the discovery of drugs that treat pulmonary arterial hypertension.
    Zolty R
    Expert Opin Drug Discov; 2023 Apr; 18(4):445-466. PubMed ID: 37013267
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pediatric pulmonary arterial hypertension due to a novel homozygous GDF2 missense variant affecting BMP9 processing and activity.
    Chomette L; Hupkens E; Romitti M; Dewachter L; Vachiéry JL; Bailly S; Costagliola S; Smits G; Tillet E; Bondue A
    Am J Med Genet A; 2023 Aug; 191(8):2064-2073. PubMed ID: 37249087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.